NCT07621159 HDM-2017 Advanced Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07621159 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 7 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07621159 is a hot trial to watch
Advanced Colorectal Adenocarcinoma is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07621159 is notable because it evaluates HDM-2017 in a Phase 1/2 design sponsored by Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07621159 |
| Official title | A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer |
| Phase / status | Phase 1/2 / Not yet recruiting |
| Intervention | HDM-2017 |
| Sponsor | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | Maximum Tolerated Dose (MTD) |
| Endpoint time frame | 30 days after the last dose of IMP] |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
This is a phase Ib/II clinical study. All participants are patients with advanced colorectal cancer (CRC). The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary anti-tumor efficacy of HDM2017 in combination with standard of care in patients with advanced CRC.
Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Maximum Tolerated Dose (MTD) (30 days after the last dose of IMP]) — The MTD will be determined using DLTs
- Recommended Phase 2 Dose (RP2D) (30 days after the last dose of IMP) — The RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data
- Type, incidence and severity of Adverse Events (30 days after the last dose of IMP) — Safety and tolerability profile assessed by the Common Terminology Criteria for Adverse Events v6.0
- Objective Response Rate (ORR) (30 days after the last dose of IMP) — ORR is defined as the proportion of subjects with BOR response of CR or PR (based on RECIST Version 1.1).
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: HDM-2017 is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. is resolved to a normalized organization record in Hangzhou, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07621159 provides a focused lens on Advanced Colorectal Adenocarcinoma development. Its value will be determined by whether HDM-2017 can convert the current Phase 1/2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
